NCT06262165已完成不适用
BILAN: Evaluation of Liver Damage in Patients With Anorexia Nervosa by Blood BIomarker ANaLysis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Identification of new blood biomarkers and hepatic cytolysis
研究概览
简要总结
The main goal of the BIocoLlection in Anorexia Nervosa-liver damage evaluation BILAN study the blood biomarkers associated with liver cytolysis.
详细描述
Study of the association between blood biomarkers and the presence of hepatic cytolysis, defined by AST and/or ALT above normal.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 15 Years 至 99 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient over 15 years old
- •Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
- •Admission to Nantes University Hospital.
排除标准
- •Chronic active viral hepatitis
- •Hemochromatosis
- •Other genetic, autoimmune.
- •Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months
- •Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)
- •Pregnant, parturient or breast-feeding women, persons deprived of liberty, adults under legal protection or unable to express their consent, persons not affiliated or not beneficiaries of a social security scheme, persons under guardianship or curators
结局指标
主要结局
Identification of new blood biomarkers and hepatic cytolysis
时间窗: Two years
Identify changes in concentration of new blood biomarkers in patients suffering from hepatic cytolysis, defined by aspartate transaminases (AST) and/or alanine transaminases (ALT) above normal values, compared to those with normal enzyme levels.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Liver Biomarkers in Anorexia NervosaAnorexia NervosaNCT05861375Nantes University Hospital43
已完成
1 期
Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionHealthyLiver DiseasesNCT02171832Boehringer Ingelheim32
已完成
1 期
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver DysfunctionHealthy VolunteersHepatic ImpairmentNCT05478603Pfizer24
已完成
1 期
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver FunctionHealthyHepatic InsufficiencyNCT01111318Boehringer Ingelheim36
招募中
不适用
Evaluation of Patients With Liver DiseaseHepatitis DHepatitis BLiver DiseaseHepatitis CNCT00001971National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)8,050